2021年3月22日 · Physicians may consider erenumab 140 mg as an option for migraine prevention in adults who have four or more migraine days a month The National Institute for Health and …

Erenumab was further investigated In May 2018, Aimovig (erenumab) became the first CGRP monoclonal antibody to be approved for the prevention of migraine in adults. Approval was …

Our slide decks bring together extensive clinical trial data supporting the efficacy and safety of the CGRP monoclonal antibodies, erenumab, fremanezumab, galcanezumab and eptinezumab, …

2021年4月27日 · The authors stress that this is class IV evidence but conclude that erenumab increased the probability of improved pain control in patients with medication resistant …

2020年11月2日 · Top line results from the Phase 4 HER-MES study of erenumab versus topiramate have demonstrated the superiority of erenumab in migraine prevention. Erenumab …

2021年2月11日 · However, when triptans were used as comparator, a signal of disproportionate reporting for spontaneous abortion was detected in association with erenumab, …

2023年11月20日 · ARISE evaluated the efficacy of erenumab 70 mg (as a subcutaneous monthly regimen) in patients with episodic migraine (defined as ≥ 4 to <15 migraine days per month …

2020年11月19日 · Erenumab (AMG 334) Galcanezumab (LY2951742) Fremanezumab (TEV-48125) Eptinezumab (ALD403) Rimegepant (BHV-3000) Ubrogepant (MK-1602) Zavegepant …

Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia 2021 Nov 7. Online ahead of print. Fremanezumab. 8. …

2020年1月22日 · In both the erenumab and galcanezumab studies, placebo effects were very small. A Phase 1 pharmacokinetics, safety and tolerability study has been published for …